Biologics MiMedx Announces Conclusion of Audit Committee’s Independent Investigation byJosh SandbergMay 23, 2019
Financial MiMedx Adopts Limited Duration Shareholder Rights Plan In Response To Delisting From Nasdaq byJosh SandbergNovember 7, 2018
Biologics MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference byJosh SandbergNovember 6, 2018
Biologics MiMedx Provides Update on Previously Announced Senior Executive Separations byJosh SandbergSeptember 24, 2018
Biologics MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix® byJosh SandbergAugust 24, 2018
Hospitals MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia byJosh SandbergAugust 9, 2018
Hospitals MiMedx Appoints Mark Graves Chief Compliance Officer To Strengthen Corporate Compliance Practices byJosh SandbergJuly 19, 2018
